Table 1 Inclusion and exclusion criteria

Inclusion Criteria

• Signed written consent

• Between the ages of 50 and 90, inclusive

• Any race or gender

• Diagnosis of nonexudative (dry) AMD in at least 1 eye having > 10 large soft drusen 63 μm in diameter, within 3,000 um of the fovea center, documented on macular exam, retinal angiography and fundus photographs

• Able to understand and comply with the requirements of the trial

• BCVA in the trial eye(s) of 20/32 to 20/125 inclusive as measured by ETDRS (logMAR)

• Subjects must not have conditions that limit the view to the fundus (eg vitreous hemorrhage, cataracts, an epiretinal membrane). All subjects with = 2+ nuclear opacities and/or significant central opacity (PSC or ASC) > 1+ will undergo Potential Acuity Meter (PAM) testing. If the vision is = 2 lines improved on PAM over standard acuity measurement then the subject will not be eligible for the trial

• Subjects must be available for a minimum trial duration of approximately 6 months

• Subjects must agree to take only the nutritional supplement that is provided during this study

• Subjects or eyes must not meet any of the exclusion criteria

Exclusion Criteria

Any of the following excluded a subject from the trial:

• Currently enrolled in an ophthalmic clinical trial

• Eyes with concomitant macular or choroidal disorders other than AMD and with indefinite signs of AMD

• Eyes with a diagnosis of exudative (wet) AMD with active subretinal neovascularization (SRNV) or CNV lesions requiring laser photocoagulation in the study eye

• Subjects with significant ocular lens opacities causing vision decrease

• Subjects with amblyopia

• Subjects with optic nerve disease (neuropathy, atrophy, papilledema), unstable glaucoma as defined by intraocular pressures greater than 25 mm Hg, 3 or more glaucoma medications, C/D of 0.8 or greater and visual fields consistent with glaucoma; history of retina-vitreous surgery, degenerative myopia, active posterior intraocular inflammatory disease, chronic use of topical ocular steroid medications, vasoproliferative retinopathies (other than AMD), rhegmatogenous retinal detachment, and inherited macular dystrophies

• Subjects with demand type pacemakers or epilepsy

• Subjects with uncontrolled hypertension (defined as diastolic of 90 or greater and systolic of 150 or greater)

• Subjects with recent history (within the previous year) of cerebral vascular disease

• manifested with transient ischemic attacks (TIA's) or cerebral vascular accidents (CVA's)

• Subjects with a history of AIDS

• Subjects who have received any previous experimental procedure in either eye or the use of any investigational drug or treatment within 30 days prior to enrolling in the trial

• Subjects who have had intraocular surgery in trial eye within 3 months prior to enrolling in the trial

• Smokers or any tobacco use